SCHEMBL21569720

SCHEMBL21569720

COc1cc(C)c(S(=O)(=O)NCCc2ccccc2O)c(C)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.50
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA5A P35218 1/20 0.45
CA9 Q16790 1/20 0.45
CA14 Q9ULX7 1/20 0.45
ALOX15 P16050 1/20 0.45
ALDH1A1 P00352 4/20 0.43
POLB P06746 2/20 0.43
NPC1 O15118 1/20 0.43
PKM P14618 1/20 0.43
RAB9A P51151 1/20 0.43
GAA P10253 2/20 0.42
MAPT P10636 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
MPO P05164 1/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21569721 0.87 L3MBTL1 (0.55) L3MBTL1CA12CA1CA2CA5A
SCHEMBL21569713 0.87 L3MBTL1 (0.66) L3MBTL1CA1CA2POLBGAA
SCHEMBL21569722 0.85 L3MBTL1 (0.50) L3MBTL1CA12CA1CA2CA5A
SCHEMBL31277189 0.77 L3MBTL1 (0.63) L3MBTL1CA12CA1CA2CA5A
SCHEMBL21550403 0.77 L3MBTL1 (0.63) L3MBTL1CA12CA1CA2CA5A
SCHEMBL2935913 0.77 ALDH1A1 (0.50) L3MBTL1CA1CA2ALDH1A1PKM
SCHEMBL21569719 0.76 L3MBTL1 (0.42) L3MBTL1CA12CA1CA2CA5A
SCHEMBL21569861 0.74 L3MBTL1 (0.71) L3MBTL1POLBGAAMAPTMEN1
SCHEMBL21569714 0.73 L3MBTL1 (0.51) L3MBTL1ALDH1A1GAAKMT2AMPO
SCHEMBL3535555 0.73 ALDH1A1 (0.60) L3MBTL1CA12CA2CA9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136545-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY GLUCOX BIOTECH AB (SE) 2025-05-01 US claimed
WO-2025078308-A1 GEL FORMULATION FOR TOPICAL OCULAR USE GLUCOX BIOTECH AB (SE) 2025-04-17 WO claimed
US-20210171456-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY GLUCOX BIOTECH AB (SE) 2021-06-10 US claimed
US-20250136545-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY GLUCOX BIOTECH AB (SE) 2025-05-01 US disclosed
US-12202790-B2 Sulfonamide derivatives having selective Nox inhibiting activity GLUCOX BIOTECH AB (SE) 2025-01-21 US disclosed
US-20210171456-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY GLUCOX BIOTECH AB (SE) 2021-06-10 US disclosed
US-20210171456-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY GLUCOX BIOTECH AB (SE) 2021-06-10 US disclosed
WO-2019215291-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY GLUCOX BIOTECH AB (SE) 2019-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12202790-B2 Sulfonamide derivatives having selective Nox inhibiting activity NOX4, NOX1, NOX5 L3MBTL1 4858/4885CA12 3389/4885CA1 3125/4885
US-20210171456-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY NOX4, NOX1, NOX5 L3MBTL1 4838/4885CA12 3484/4885CA1 3231/4885
US-20250136545-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY NOX4, NOX1, NOX5 L3MBTL1 4838/4885CA12 3484/4885CA1 3231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.